Loading…
← CockpitCompetitor Analysis › 603658.SS Autobio Diagnostics Co., Ltd. Class AOpen in the cockpit ↗

Autobio Diagnostics Co., Ltd. Class A603658.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Leading Chinese in-vitro diagnostics maker selling immunoassay and chemistry analyzers plus reagents to hospital labs.

≈ A Chinese Abbott Diagnostics/Roche Diagnostics for IVDMomentum leader 98
Mkt cap
$3.36B
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$36.5M
20-day average traded
Fwd P/E
20.3×
forward earnings
ROIC−WACC
+7.6 pp
WACC 5.1%
Hurdle
-8 pp
Req g minus delivered
Next earnings
149 days
16 Apr 2027
Close · CNYCN¥38.82
1D-0.3%
1W-0.6%
1M+13.5%
3M+19.8%
6M+15.6%
YTD+9.6%
1Y+1.9%
ATR %2.8%
52w lowhigh3.3% off high

What Autobio Diagnostics does

Leading Chinese in-vitro diagnostics maker selling immunoassay and chemistry analyzers plus reagents to hospital labs.

Places analyzers in hospital labs and earns recurring revenue from the reagents consumed on every test, which carry more of the profit than the instrument. Hospital buying runs largely through public procurement and tenders.

In one line: A Chinese Abbott Diagnostics/Roche Diagnostics for IVD.

Products and services

  • Chemiluminescence immunoassay analyzers
  • IVD reagents
  • Clinical chemistry analyzers
  • Microbiology testing systems

Customers

  • Hospital clinical laboratories

Where it sits in the supply chain

  • Health Care
  • In-vitro diagnostics
  • Immunoassay & clinical chemistry…

What could go right

  • Hospital lab automation demand
  • Overseas IVD expansion

What could go wrong

  • Volume-based procurement price pressure

Moat: narrow (installed base, switching costs). Analyzer-reagent lock-in once a hospital lab adopts its instrument platform.

Headquarters: Zhengzhou, Henan, China · Founded: 1998 · Employees: 5,700

Named competitors

Autobio Diagnostics at a glance

Size Autobio Diagnostics (603658.SS) is a China Health Care company (Medical Specialties) with a market value of $3.36B, the 724th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥38.82 on 18 Nov 2026.

Performance Over six months the shares gained 15.6%, against +3.2% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 2.9% over the last twelve months (peer median +7.4%); the operating margin is 25.4% (peer median 7.3%).

Valuation It trades at 20.3× forward earnings against a peer median of 27.2× (5th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.6 points above its cost of capital (5.1% WACC).

Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026603658.SS 116Peer median 104
Six months, rebased to 100: Autobio Diagnostics against the median of its 20 peers (local-currency closes).

Autobio Diagnostics financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.34BCN¥4.19BCN¥4.44BCN¥4.39BCN¥4.40B
Revenue growth—-6%+1%0%—
Gross profitCN¥3.21BCN¥2.59BCN¥2.76BCN¥2.71BCN¥2.49B
EBITDAn/aCN¥1.56BCN¥1.61BCN¥1.66BCN¥1.58B
Net incomeCN¥1.06BCN¥1.07BCN¥1.19BCN¥1.22BCN¥1.17B
Free cash flowCN¥539MCN¥738MCN¥649MCN¥569MCN¥629M
Capital expenditureCN¥494MCN¥604MCN¥664MCN¥900MCN¥938M
Total debtCN¥972MCN¥996MCN¥1.04BCN¥1.04BCN¥873M

Quarterly statements and history in the cockpit →

Autobio Diagnostics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%TMDXPLSEAXGN688301603301AMBU-B4203300003IRTCAFXTECN6030146881141SXPNVST002432CDNAFIEATRCCOTN603658.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Autobio Diagnostics is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×100×200×TMDXAXGN688301603301AMBU-B4203300003IRTCTECN603014NVST002432CDNAATRC603658.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Autobio Diagnostics is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%TMDXAXGN603301AMBU-B4203300003IRTCTECN603014688114NVST002432FIE603658.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Autobio Diagnostics is the large dot.

Autobio Diagnostics competitors and peer comparison

Head to head with its named competitors (603658.SS vs ABT vs 300760.SZ vs 300832.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Autobio Diagnostics 603658.SS$3.36B+16%+3%25%20.3×-0.4%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
Shenzhen Mindray Bio-Medical Electronics 300760.SZ$33.6B+15%+5%28%27.3×1.0%
Shenzhen New Industries Biomedical Engineering 300832.SZ$7.50B+21%+7%43%26.9×2.9%

How Autobio Diagnostics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Autobio Diagnostics against its 20 peers (data as of 18 Nov 2026)
Measure603658.SSPeer medianRank in peer set
1-month return+13.5%-0.2%5th highest of 21
6-month return+15.6%+3.2%10th highest of 21
Distance from 52-week high-3.3%-24.1%highest of 21
Revenue growth (TTM)+2.9%+7.4%7th lowest of 21
Operating margin25.4%7.3%highest of 20
Forward P/E20.3×27.2×5th cheapest of 19
Growth the price implies (Req g, 7 yrs)-0.4%12.6%4th least demanding of 17
Growth delivered (Del g)+7.2%+9.5%7th lowest of 17
Hurdle (Req g minus delivered)-7.6 pp+1.7 pp4th least demanding of 17
ROIC minus cost of capital+7.6 pp-1.6 pp2nd highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a

Questions

Who are Autobio Diagnostics's main competitors?
Named competitors: Roche Diagnostics (private or unlisted), Abbott Diagnostics (ABT), Mindray (300760.SZ), New Industries Biomedical (300832.SZ). The cockpit's measured peer set (industry) also includes TransMedics (TMDX), Pulse Biosciences (PLSE), Axogen (AXGN), iRay Technology (688301.SS), Zhende Medical (603301.SS), Ambu A/S (AMBU-B.CO).
Is Autobio Diagnostics expensive compared with its peers?
On forward p/e it trades at 20.3× against a peer median of 27.2×, 5th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Autobio Diagnostics stock performed?
Over six months to 18 Nov 2026 the shares returned +15.6% against +3.2% for the median peer; over one year +1.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.